Selected research
Market Structure
Global Neurometabolic Disorders Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Neurometabolic Disorders market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Neurometabolic Disorders is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Neurometabolic Disorders include Amicus, Amicus Therapeutics, Biomarin, Biosidus, Dong-A Socio Group, ExSAR Corporation, Genzyme, Greencross and Greenovation Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Neurometabolic Disorders market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Neurometabolic Disorders and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Neurometabolic Disorders revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neurometabolic Disorders market size, projected growth trends, production technologies, key applications, and end-use industries.
Neurometabolic Disorders Segment by Company
Amicus
Amicus Therapeutics
Biomarin
Biosidus
Dong-A Socio Group
ExSAR Corporation
Genzyme
Greencross
Greenovation Biotech
ISU Abxis
JCR Pharmaceuticals
Lixte Biotechnology
Neuraltus Pharmaceuticals
Pharming Group
Protalix
Protalix BioTherapeutics
Shire
UAB Proforma
Neurometabolic Disorders Segment by Type
Pompe Disease
Mucopolysaccharidosis VI
Gaucher’s Disease
Fabry Disease
Other
Neurometabolic Disorders Segment by Application
Oral
Parenteral
Neurometabolic Disorders Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurometabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurometabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurometabolic Disorders.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neurometabolic Disorders in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurometabolic Disorders industry.
Chapter 3: Detailed analysis of Neurometabolic Disorders companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurometabolic Disordersrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pompe Disease
- Mucopolysaccharidosis VI
- Gaucher’s Disease
- Fabry Disease
- Other
Applications
- Oral
- Parenteral
Companies covered
- Amicus
- Amicus Therapeutics
- Biomarin
- Biosidus
- Dong-A Socio Group
- ExSAR Corporation
- Genzyme
- Greencross
- Greenovation Biotech
- ISU Abxis
- JCR Pharmaceuticals
- Lixte Biotechnology
- Neuraltus Pharmaceuticals
- Pharming Group
- Protalix
- Protalix BioTherapeutics
- Shire
- UAB Proforma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Pompe Disease
- 1.2.3 Mucopolysaccharidosis VI
- 1.2.4 Gaucher’s Disease
- 1.2.5 Fabry Disease
- 1.2.6 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Neurometabolic Disorders Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Oral
- 1.3.3 Parenteral
- 1.4 Global Market Growth Prospects
- 1.5 Global Neurometabolic Disorders Growth Trends by Region
- 1.5.1 Global Neurometabolic Disorders Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Neurometabolic Disorders Market Size by Region (2021-2026)
- 1.5.3 Neurometabolic Disorders Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Neurometabolic Disorders Market Dynamics
- 2.1 Neurometabolic Disorders Industry Trends
- 2.2 Neurometabolic Disorders Industry Drivers
- 2.3 Neurometabolic Disorders Industry Opportunities and Challenges
- 2.4 Neurometabolic Disorders Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Neurometabolic Disorders Revenue by Company (2021-2026)
- 3.2 Global Neurometabolic Disorders Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Neurometabolic Disorders Key Company Head office and Area Served
- 3.4 Global Neurometabolic Disorders Company, Product Type & Application
- 3.5 Global Neurometabolic Disorders Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Neurometabolic Disorders Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Neurometabolic Disorders Players Market Share by Revenue in 2025
- 3.6.3 2025 Neurometabolic Disorders Tier 1, Tier 2, and Tier 3
4 Neurometabolic Disorders Market by Type
- 4.1 Global Neurometabolic Disorders Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Neurometabolic Disorders Market Size by Type (2021-2032)
- 4.3 Global Neurometabolic Disorders Market Size Share by Type (2021-2032)
5 Neurometabolic Disorders Market by Application
- 5.1 Global Neurometabolic Disorders Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Neurometabolic Disorders Market Size by Application (2021-2032)
- 5.3 Global Neurometabolic Disorders Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Amicus
- 6.1.1 Amicus Company Information
- 6.1.2 Amicus Business Overview
- 6.1.3 Amicus Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Amicus Neurometabolic Disorders Product Portfolio
- 6.1.5 Amicus Recent Developments
- 6.2 Amicus Therapeutics
- 6.2.1 Amicus Therapeutics Company Information
- 6.2.2 Amicus Therapeutics Business Overview
- 6.2.3 Amicus Therapeutics Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Amicus Therapeutics Neurometabolic Disorders Product Portfolio
- 6.2.5 Amicus Therapeutics Recent Developments
- 6.3 Biomarin
- 6.3.1 Biomarin Company Information
- 6.3.2 Biomarin Business Overview
- 6.3.3 Biomarin Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Biomarin Neurometabolic Disorders Product Portfolio
- 6.3.5 Biomarin Recent Developments
- 6.4 Biosidus
- 6.4.1 Biosidus Company Information
- 6.4.2 Biosidus Business Overview
- 6.4.3 Biosidus Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Biosidus Neurometabolic Disorders Product Portfolio
- 6.4.5 Biosidus Recent Developments
- 6.5 Dong-A Socio Group
- 6.5.1 Dong-A Socio Group Company Information
- 6.5.2 Dong-A Socio Group Business Overview
- 6.5.3 Dong-A Socio Group Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Dong-A Socio Group Neurometabolic Disorders Product Portfolio
- 6.5.5 Dong-A Socio Group Recent Developments
- 6.6 ExSAR Corporation
- 6.6.1 ExSAR Corporation Company Information
- 6.6.2 ExSAR Corporation Business Overview
- 6.6.3 ExSAR Corporation Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 ExSAR Corporation Neurometabolic Disorders Product Portfolio
- 6.6.5 ExSAR Corporation Recent Developments
- 6.7 Genzyme
- 6.7.1 Genzyme Company Information
- 6.7.2 Genzyme Business Overview
- 6.7.3 Genzyme Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Genzyme Neurometabolic Disorders Product Portfolio
- 6.7.5 Genzyme Recent Developments
- 6.8 Greencross
- 6.8.1 Greencross Company Information
- 6.8.2 Greencross Business Overview
- 6.8.3 Greencross Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Greencross Neurometabolic Disorders Product Portfolio
- 6.8.5 Greencross Recent Developments
- 6.9 Greenovation Biotech
- 6.9.1 Greenovation Biotech Company Information
- 6.9.2 Greenovation Biotech Business Overview
- 6.9.3 Greenovation Biotech Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Greenovation Biotech Neurometabolic Disorders Product Portfolio
- 6.9.5 Greenovation Biotech Recent Developments
- 6.10 ISU Abxis
- 6.10.1 ISU Abxis Company Information
- 6.10.2 ISU Abxis Business Overview
- 6.10.3 ISU Abxis Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 ISU Abxis Neurometabolic Disorders Product Portfolio
- 6.10.5 ISU Abxis Recent Developments
- 6.11 JCR Pharmaceuticals
- 6.11.1 JCR Pharmaceuticals Company Information
- 6.11.2 JCR Pharmaceuticals Business Overview
- 6.11.3 JCR Pharmaceuticals Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio
- 6.11.5 JCR Pharmaceuticals Recent Developments
- 6.12 Lixte Biotechnology
- 6.12.1 Lixte Biotechnology Company Information
- 6.12.2 Lixte Biotechnology Business Overview
- 6.12.3 Lixte Biotechnology Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Lixte Biotechnology Neurometabolic Disorders Product Portfolio
- 6.12.5 Lixte Biotechnology Recent Developments
- 6.13 Neuraltus Pharmaceuticals
- 6.13.1 Neuraltus Pharmaceuticals Company Information
- 6.13.2 Neuraltus Pharmaceuticals Business Overview
- 6.13.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio
- 6.13.5 Neuraltus Pharmaceuticals Recent Developments
- 6.14 Pharming Group
- 6.14.1 Pharming Group Company Information
- 6.14.2 Pharming Group Business Overview
- 6.14.3 Pharming Group Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Pharming Group Neurometabolic Disorders Product Portfolio
- 6.14.5 Pharming Group Recent Developments
- 6.15 Protalix
- 6.15.1 Protalix Company Information
- 6.15.2 Protalix Business Overview
- 6.15.3 Protalix Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Protalix Neurometabolic Disorders Product Portfolio
- 6.15.5 Protalix Recent Developments
- 6.16 Protalix BioTherapeutics
- 6.16.1 Protalix BioTherapeutics Company Information
- 6.16.2 Protalix BioTherapeutics Business Overview
- 6.16.3 Protalix BioTherapeutics Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio
- 6.16.5 Protalix BioTherapeutics Recent Developments
- 6.17 Shire
- 6.17.1 Shire Company Information
- 6.17.2 Shire Business Overview
- 6.17.3 Shire Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Shire Neurometabolic Disorders Product Portfolio
- 6.17.5 Shire Recent Developments
- 6.18 UAB Proforma
- 6.18.1 UAB Proforma Company Information
- 6.18.2 UAB Proforma Business Overview
- 6.18.3 UAB Proforma Neurometabolic Disorders Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 UAB Proforma Neurometabolic Disorders Product Portfolio
- 6.18.5 UAB Proforma Recent Developments
7 North America
- 7.1 North America Neurometabolic Disorders Market Size (2021-2032)
- 7.2 North America Neurometabolic Disorders Market Size by Type
- 7.2.1 North America Neurometabolic Disorders Market Size by Type (2021-2026)
- 7.2.2 North America Neurometabolic Disorders Market Size by Type (2027-2032)
- 7.2.3 North America Neurometabolic Disorders Market Share by Type (2021-2032)
- 7.3 North America Neurometabolic Disorders Market Size by Application
- 7.3.1 North America Neurometabolic Disorders Market Size by Application (2021-2026)
- 7.3.2 North America Neurometabolic Disorders Market Size by Application (2027-2032)
- 7.3.3 North America Neurometabolic Disorders Market Share by Application (2021-2032)
- 7.4 North America Neurometabolic Disorders Market Size by Country
- 7.4.1 North America Neurometabolic Disorders Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Neurometabolic Disorders Market Size by Country (2021-2026)
- 7.4.3 North America Neurometabolic Disorders Market Size by Country (2027-2032)
- 7.4.4 North America Neurometabolic Disorders Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Neurometabolic Disorders Market Size (2021-2032)
- 8.2 Europe Neurometabolic Disorders Market Size by Type
- 8.2.1 Europe Neurometabolic Disorders Market Size by Type (2021-2026)
- 8.2.2 Europe Neurometabolic Disorders Market Size by Type (2027-2032)
- 8.2.3 Europe Neurometabolic Disorders Market Share by Type (2021-2032)
- 8.3 Europe Neurometabolic Disorders Market Size by Application
- 8.3.1 Europe Neurometabolic Disorders Market Size by Application (2021-2026)
- 8.3.2 Europe Neurometabolic Disorders Market Size by Application (2027-2032)
- 8.3.3 Europe Neurometabolic Disorders Market Share by Application (2021-2032)
- 8.4 Europe Neurometabolic Disorders Market Size by Country
- 8.4.1 Europe Neurometabolic Disorders Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Neurometabolic Disorders Market Size by Country (2021-2026)
- 8.4.3 Europe Neurometabolic Disorders Market Size by Country (2027-2032)
- 8.4.4 Europe Neurometabolic Disorders Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Neurometabolic Disorders Market Size (2021-2032)
- 9.2 China Neurometabolic Disorders Market Size by Type
- 9.2.1 China Neurometabolic Disorders Market Size by Type (2021-2026)
- 9.2.2 China Neurometabolic Disorders Market Size by Type (2027-2032)
- 9.2.3 China Neurometabolic Disorders Market Share by Type (2021-2032)
- 9.3 China Neurometabolic Disorders Market Size by Application
- 9.3.1 China Neurometabolic Disorders Market Size by Application (2021-2026)
- 9.3.2 China Neurometabolic Disorders Market Size by Application (2027-2032)
- 9.3.3 China Neurometabolic Disorders Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Neurometabolic Disorders Market Size (2021-2032)
- 10.2 Asia Neurometabolic Disorders Market Size by Type
- 10.2.1 Asia Neurometabolic Disorders Market Size by Type (2021-2026)
- 10.2.2 Asia Neurometabolic Disorders Market Size by Type (2027-2032)
- 10.2.3 Asia Neurometabolic Disorders Market Share by Type (2021-2032)
- 10.3 Asia Neurometabolic Disorders Market Size by Application
- 10.3.1 Asia Neurometabolic Disorders Market Size by Application (2021-2026)
- 10.3.2 Asia Neurometabolic Disorders Market Size by Application (2027-2032)
- 10.3.3 Asia Neurometabolic Disorders Market Share by Application (2021-2032)
- 10.4 Asia Neurometabolic Disorders Market Size by Country
- 10.4.1 Asia Neurometabolic Disorders Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Neurometabolic Disorders Market Size by Country (2021-2026)
- 10.4.3 Asia Neurometabolic Disorders Market Size by Country (2027-2032)
- 10.4.4 Asia Neurometabolic Disorders Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Neurometabolic Disorders Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Neurometabolic Disorders Market Size by Type
- 11.2.1 South America, Middle East & Africa Neurometabolic Disorders Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Neurometabolic Disorders Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Neurometabolic Disorders Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Neurometabolic Disorders Market Size by Application
- 11.3.1 South America, Middle East & Africa Neurometabolic Disorders Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Neurometabolic Disorders Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Neurometabolic Disorders Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Neurometabolic Disorders Market Size by Country
- 11.4.1 South America, Middle East & Africa Neurometabolic Disorders Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Neurometabolic Disorders Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Neurometabolic Disorders Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Neurometabolic Disorders Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst